HIV Treatment Guidelines
All adults with HIV should start antiretroviral therapy (ART) immediately upon diagnosis, with dolutegravir plus tenofovir alafenamide/emtricitabine (DTG/TAF/FTC) as the preferred first-line regimen, or bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) as an equally effective alternative. 1
First-Line Antiretroviral Regimens
The 2024 International Antiviral Society-USA guidelines provide clear hierarchical recommendations 1:
Preferred 3-Drug Regimens:
- Bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC)
- Dolutegravir (DTG) + tenofovir alafenamide/emtricitabine (TAF/FTC)
- Dolutegravir (DTG) + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
All three regimens have equivalent efficacy and are listed alphabetically without preference ranking 1.
Preferred 2-Drug Regimen:
Dolutegravir/lamivudine (DTG/3TC) is the only recommended 2-drug initial regimen, but has critical exclusion criteria 1:
- Do NOT use if:
- HIV RNA ≥500,000 copies/mL
- Hepatitis B co-infection present
- Lamivudine resistance detected
- During pregnancy (limited data)
- CD4+ count <200/μL (limited data)
Because DTG/3TC requires baseline laboratory results to exclude these contraindications, it cannot be started immediately at diagnosis 1.
Alternative Regimens:
- Dolutegravir + tenofovir alafenamide/lamivudine (TAF/3TC)
- Boosted darunavir (DRV/r or DRV/c) + TXF/XTC (when integrase inhibitor resistance suspected, particularly after long-acting cabotegravir PrEP exposure) 1
Special Population Considerations
Pregnancy
Dolutegravir with TAF/FTC (or TDF/XTC if TAF/FTC unavailable) is the recommended regimen for pregnant persons and those planning pregnancy 1. This represents a significant shift from older guidance due to:
- High antiviral efficacy
- Low rates of adverse birth outcomes
- Reassuring safety data from first-trimester exposures
BIC/TAF/FTC is an alternative regimen with sufficient drug levels during pregnancy and low birth defect rates 1. Persons already on BIC/TAF/FTC who become pregnant should continue if tolerated and effective.
If dolutegravir is not an option or after long-acting cabotegravir PrEP failure:
- Use TXF/XTC plus darunavir 600 mg twice daily plus ritonavir 100 mg 1
Hepatitis B Co-infection
Critical consideration: Tenofovir (TAF or TDF) plus emtricitabine or lamivudine provides dual HIV/HBV activity 1.
Do NOT use DTG/3TC in HBV co-infection because it lacks adequate HBV coverage 1. This is a common pitfall—always check HBV surface antigen before considering 2-drug regimens.
For HBV co-infected patients, preferred regimens are:
- BIC/TAF/FTC
- DTG + TAF/FTC
- DTG + TDF/FTC
Warning about 2-drug switches: Case reports demonstrate HBV reactivation and even fulminant hepatitis requiring liver transplantation when switching to non-HBV-active 2-drug regimens 2. Even patients with isolated HBV core antibody or vaccine non-responders are at risk.
Renal Impairment
Tenofovir alafenamide (TAF) is strongly preferred over tenofovir disoproxil fumarate (TDF) in patients with renal concerns due to lower nephrotoxicity risk 1, 3.
Key renal considerations:
- TDF-treated patients show 1.76-fold increased CKD progression risk compared to untreated patients 3
- Entecavir and TAF show comparable CKD progression risks to untreated patients—significantly better than TDF 3
- Monitor estimated glomerular filtration rate (eGFR) at baseline, 2-4 weeks after initiation, then every 3-6 months
- Consider switching from TDF to TAF if eGFR declining
Monitoring Schedule
Baseline Laboratory Evaluation:
- HIV RNA (viral load)
- CD4+ lymphocyte count
- HIV genotypic resistance testing (critical—do not wait for results to start preferred 3-drug regimens)
- Hepatitis B surface antigen, core antibody, surface antibody
- Hepatitis C antibody
- Complete blood count, comprehensive metabolic panel
- Lipid panel
- Pregnancy test (if applicable)
- HLA-B*5701 testing (if considering abacavir)
Follow-up Monitoring:
- HIV RNA at 4 weeks, then every 3-6 months once suppressed
- CD4+ count every 3-6 months until consistently >350 cells/μL and virologically suppressed for >2 years, then can extend to annually
- Renal function (eGFR, urinalysis) every 6-12 months, more frequently with TDF or baseline renal disease
- Hepatic function panels every 6-12 months
- Lipid panels annually
Special Clinical Scenarios
Starting ART Before Resistance Testing Results
You can and should start immediately with preferred 3-drug regimens (BIC/TAF/FTC or DTG/TAF/FTC) without waiting for resistance results 1. These regimens have high genetic barriers to resistance.
Exception: If patient acquired HIV while on TXF/XTC for PrEP, start dolutegravir or bictegravir with TXF/XTC, but modify based on resistance results when available 1.
If integrase inhibitor resistance suspected (particularly after long-acting cabotegravir PrEP exposure): Start boosted darunavir-based regimen, then switch to InSTI or NNRTI-based therapy once resistance testing excludes resistance 1.
Tuberculosis Co-treatment
Rifampin creates significant drug-drug interactions with most ART regimens 1:
Compatible regimens with rifampin:
- DTG (50 mg twice daily—note the dose increase) + TXF/XTC
- Efavirenz-based regimens
NOT recommended with rifampin:
- Bictegravir
- Boosted darunavir
- Doravirine
- Elvitegravir/cobicistat
- Long-acting cabotegravir/rilpivirine
- Rilpivirine
- DTG/3TC or BIC/TAF/FTC (inadequate data)
Rifabutin (150 mg) can substitute for rifampin with boosted protease inhibitor regimens if necessary 1.
Common Pitfalls to Avoid
- Starting DTG/3TC without baseline labs—you must exclude HBV, high viral load, and resistance first
- Missing HBV co-infection—always check HBV surface antigen before initiating therapy
- Using TDF in patients with renal disease—switch to TAF-based regimens
- Continuing non-HBV-active regimens in HBV core antibody-positive patients—risk of reactivation exists
- Forgetting to dose-adjust DTG to twice daily with rifampin
- Not starting ART immediately—treatment is recommended for all persons with HIV regardless of CD4 count 1, 4